Alnylam's Cash Machine Is Working. The Stock Is Pretending It Isn't.

The stock has lost nearly half its value over the past year, dropping from above $495 to around $248 stock has fallen 46.8% over the past year. Wells Fargo cut its price target by $60 Wells Fargo slashed its price target to $256 from $316. Jefferies flagged slowing demand Jefferies flagged slowing. The story you'd expect to follow is another one about why a gene-silencing pioneer is running into trouble.

The actual story is harder to ignore when you look at the cash-flow path.

Alnylam, the RNA interference company behind the injectable drug AMVUTTRA, generated $820 million in free cash flow over the trailing twelve months. Twelve months ago, the number was negative $43 million. Operating margins moved from a loss of 7.9% in fiscal 2024 to 17.5% at the half-year mark of 2026. The company went from negative equity in early 2024 to $1.35 billion in shareholders' equity, sitting on $1.7 billion in cash against $4.2 billion in total debt — net cash of $2.3 billion.

That is not a company whose thesis is breaking. That is a company whose financial transformation just finished its first full proof period.

The old story caught up to a new business

The market has punished Alnylam for two specific events earlier this year. In July, the company reported second-quarter revenues of $1.29 billion — up 67% year-over-year, with AMVUTTRA pulling in $1.01 billion, up 106% — and then immediately cut its full-year TTR revenue guidance from $4.4 to $4.7 billion down to $4.2 to $4.5 billion Revises Full-Year 2026 TTR Net Product Revenue Guidance from $4,400 to $4,700 Million to $4,200 to $4,500. Alnylam explained the cut as pent-up demand from ATTR-CM patients normalizing after the FDA approval normalization of growth in second-line volume after satisfying pent-up demand, rather than a structural demand problem.

Wells Fargo reacted by slashing its price target from $316 to $256. Jefferies flagged the demand slowdown. The stock extended its slide.

But the guide cut needs context. The revised $4.2 to $4.5 billion midpoint still represents approximately 75% growth over 2025 full-year TTR revenue of roughly $2.5 billion. The company also raised its collaboration and royalty revenue guidance — from $400 to $500 million up to $575 to $625 million Net Revenues from Collaborations and Royalties: Raised to $575–$625 million previously $400–$500 million — driven by royalties from Zilebesiran and Leqvio. Total net product revenue guidance now sits at $4.7 to $5.1 billion for the year.

The market heard "demand slowing." The numbers say "the explosive first-year adoption wave is normalizing, and the company is still growing fast enough to be growing fast."

The financial transformation the stock is ignoring

What you're supposed to do with this kind of information — whether or not you own the stock — is separate the tape from the business. The tape tells you that sentiment has gone negative. The business tells you something different.

Free cash flow is where the evidence concentrates. In 2024, Alnylam burned cash on a trailing-twelve-month basis. By the end of 2025, FCF had swung to $465 million. By mid-2026, it was $820 million, up more than 11 times year-over-year. The FCF margin sits at 15%, meaning roughly one out of every seven dollars in revenue now reaches the bottom line as discretionary cash.

The margin quality is real. Gross margins remain above 80%. Operating margin went from a negative position in fiscal 2024 to 17.5% at the current period. ROIC — return on invested capital — stands at 55%. That is the kind of capital efficiency you see in businesses that have figured out how to scale without proportionally scaling costs.

The balance sheet repair tells the same story. The company had negative equity in early 2024, which for a pharmaceutical firm means accumulated losses exceeded retained value. Today, equity is $1.35 billion and growing. Total equity rose from $67 million at the end of fiscal 2024 to $1.35 billion by mid-2026. The net cash position of $2.3 billion gives Alnylam an enormous optionality buffer — it can fund its pipeline, make acquisitions, or simply sit on cash while the revenue engine compounds.

Why the market is still pricing the old story

The current price gives Alnylam a market capitalization of $33 billion and an enterprise value of $31 billion. The forward P/E is deeply negative — a mechanical artifact of how the multiples are calculated when forward estimates haven't caught up to the earnings transformation — but the trailing P/E of 43x tells the market's actual framing: investors are applying a growth-stock multiple to what they still see as a drug launch with unresolved adoption questions.

The PEG ratio, however, sits at 0.12. That figure only makes sense if you accept the revenue growth rate embedded in it — 95% year-over-year — and believe that kind of growth can sustain for multiple periods. If it can't, the PEG collapses. If it can, the multiple compression is the entry signal.

That is where the market's hesitation makes sense. AMVUTTRA accounts for the overwhelming majority of the revenue story — $1.01 billion of $1.29 billion in Q2. When one product drives 78% of your total revenue, concentration risk is a real concern. Any slowdown, competitive threat, or reimbursement issue in the ATTR market reverberates through the entire business.

The clinical data is supposed to ease that concern. At the ESC Congress in late August, Alnylam presented subgroup results from its HELIOS-B trial showing that AMVUTTRA reduced all-cause mortality and recurrent cardiovascular events consistently treatment effect on the primary composite endpoint of all-cause mortality and recurrent cardiovascular events through 33-36 months was consistent irrespective of baseline tafamidis use, whether patients were already on tafamidis — the standard-of-care competitor from Akcea/Acorda — or not. The treatment effect held across the full follow-up period of 33 to 36 months. Post-hoc analysis showed AMVUTTRA patients had 42% fewer gastrointestinal adverse events and 41% fewer nervous system events Gastrointestinal disorders: 42% lower rate; Nervous system disorders: 41% lower rate compared with placebo.

That is the kind of data that supports broader adoption and label positioning, not the kind that triggers a sell signal.

The pipeline provides a secondary layer of de-risking, though it should not carry the thesis. Zilebesiran for hypertension is in Phase 3 outcomes trials Zilebesiran is being evaluated in the ongoing global Phase 3 CV outcomes trial, ZENITH, which is a huge addressable market if the data holds. Nucresiran for primary hyperoxaluria, mivelsiran for Alzheimer's-related amyloid, and candidates in obesity and Huntington's disease are all at earlier stages. They are optionality, not proof.

What would break the case

The strongest bear argument is not about the past — it's about the shape of AMVUTTRA's growth curve going forward. If pent-up demand normalization turns out to be the start of a sustained deceleration, if tafamidis competition captures more share than expected, or if the ATTR-CM market is smaller than the current trajectory implies, then the revenue growth rate falls and the multiple the market is paying becomes too rich for the new growth reality.

The specific condition that must hold is this: AMVUTTRA revenue needs to keep growing at a rate that justifies a high-multiple biotech valuation. The revised 2026 guidance midpoint of roughly $4.35 billion in TTR revenue implies about 75% growth — which would justify the multiple. But that 75% needs to carry credibility into 2027.

A second break condition is simpler: the free cash flow machine needs to keep working. If the $820 million FCF figure was a one-period blip — driven by timing of R&D spend or deferred SG&A related to the ATTR-CM launch — then the financial transformation story loses its anchor. The Q1 2026 FCF was $643 million, so there is already a second consecutive period of strong cash generation. But the bear would say: watch the full year, not just two quarters.

There is no need for a complex DCF model to evaluate this case. The question is straightforward — can a business that just went from negative cash flow to $820 million in FCF, with 15% FCF margins and a net cash balance of $2.3 billion, compound from here? The market is currently answering no, or at least asking for more proof before saying yes.

The numbers available right now suggest otherwise. But the concentration on one drug and the uncertainty about whether second-year growth sustains are legitimate reasons the stock has fallen.

The setup is that the operating evidence has moved sharply in the right direction while the market narrative is still anchored to the old fears about profitability and demand normalization. Whether that divergence narrows because the numbers keep improving — or because the guidance disappoints again — depends on what happens in the ATTR market over the next four quarters.

That's the proof path. That's also the tripwire.